Investigations

The CytoDyn board of directors fired Nader Pourhassan in early 2022 as the company faced US FDA scrutiny over his comments about HIV and COVID-19 candidate leronlimab and as investors sued the firm.

The Paris-headquartered giant has put the spotlight on its extensive investments at home.

Organon is looking for a new CEO after an internal investigation uncovered “improper wholesaler sales practices” relating to its Nexplanon implant. The firm will not revise any previously issued financial statements, despite saying that the tactics helped meet revenue expectations.

“Company employee diverted legitimate packaging and customer information to distribute counterfeit, adulterated product,” says Green Lumber. It’s “working cooperatively with FDA and law enforcement to address this matter.”

Congress launched an inquiry into 23andMe amid privacy concerns following its bankruptcy, particularly regarding the potential sale of sensitive user data. Additionally, a Cybernews report gave 40 DNA testing firms an average cybersecurity grade of D, citing widespread vulnerabilities and data breaches, along with inadequate public information about their security practices.